okyopharma.com - OKYO Trailing Twelve Months Revenue Growth

Graphic logo of okyopharma.com (OKYO)

Stable demand for dry eye therapy guarantees OKYO Pharma Limited (OKYO) long-term rent. The sales dynamics over the last 12 months year-over-year confirm this trend, where 0.00 is recorded as the baseline value. R&D efforts in the US and UK strengthen the company's position, while patent protection and stringent FDA requirements create significant barriers to entry for new market players.

OKYO Pharma Limited (OKYO) Revenue Growth YoY (Last 12 Months): for the period 02/11/2024 - 11/19/2026

OKYO Pharma Limited (OKYO) - metric breakdowns and financial figures

- market price and analyst price targets:
Summary company analytics:OKYO (OKYO Pharma)
Finished products of OKYO Pharma Inc

For OKYO Pharma Limited (OKYO), which focuses on dry eye medications, the year-over-year (12-month) relative revenue growth rate serves as an indicator of commercial viability. This metric captures the percentage change in sales volume over a rolling year compared to the same period of the previous cycle. The calculation is based on market consensus, bypassing official reporting delays. For a single-product business, this price action reflects the success of the drug's implementation, while steady growth confirms scaling within the mass market.